Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00274313 · ClinicalTrials.gov registry record · Phase 1
Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients
A Phase 1 study of Cystic Fibrosis, sponsored by Parion Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 15
- Study locations
NCT00274313 is a Phase 1 study of Cystic Fibrosis that has completed, run by Parion Sciences. The registered enrollment target is 40 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (78% lower). The trial reports 15 study locations across 11 states.
The verdict
NCT00274313, a Phase 1 study of Cystic Fibrosis, has completed, sponsored by Parion Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 15
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of a new inhaled sodium-channel blocker called 552-02 in teens and adults with cystic fibrosis. 552-02 will be inhaled once a day for 14 days using a nebulizer. A small subgroup of patients will donate blood samples for pharmacokinetic analysis to see how 552-02 is absorbed into the blood and eliminated after 14 days of treatment.
Conditions Studied
Interventions
- DRUG 552-02
Study Locations (15)
Pennsylvania
- Hershey Medical Center - Hershey
- Children's Hospital of Philadelphia - Philadelphia
- University of Pittsburgh - Pittsburgh
California
- University of California at San Diego - San Diego
- University of California at San Francisco Medical Center - San Francisco
Florida
- Nemours Children's Clinic - Orlando
- University of South Florida - Tampa
Colorado
- The Children's Hospital - Denver
Illinois
- Children's Memorial Hospital - Chicago
Nebraska
- University of Nebraska Medical Center - Omaha
New Jersey
- Morristown Memorial Hospital - Morristown
New York
- State University of New York Upstate - Syracuse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2006-01 |
| Est. Completion | 2006-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00274313
The ClinicalTrials.gov registry entry for NCT00274313 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (78% lower). The listed sponsor is Parion Sciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which 552-02 is the first listed.
NCT00274313 reports 15 study locations spanning 11 distinct geographic areas - top geographies include Pennsylvania, California, Florida.
Frequently Asked Questions
What is clinical trial NCT00274313 about?
NCT00274313 is a clinical study titled "Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients". The purpose of this study is to evaluate the safety and tolerability of a new inhaled sodium-channel blocker called 552-02 in teens and adults with cystic fibrosis. 552-02 will be inhaled once a day for 14 days using a nebulizer. A small subgroup of patients will donate blood samples for pharmacokin...
What is the current status of trial NCT00274313?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2006-01. Estimated completion is 2006-08.
What conditions does trial NCT00274313 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT00274313?
The interventions under investigation include: 552-02 (DRUG).
Who is sponsoring clinical trial NCT00274313?
This trial is sponsored by Parion Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00274313 being conducted?
This trial has 15 study locations across California, Colorado, Florida, Illinois, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
RECRUITING · Phase 1
-
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
RECRUITING · Phase 1
-
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
RECRUITING · Phase 1
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.